Awardee OrganizationHOSPITAL FOR SICK CHLDRN (TORONTO)
Description
Abstract Text
Lung disease is the major contributor to morbidity and the primary cause of mortality of CF patients. The lung disease is characterized by pulmonary obstruction and tissue damage due to chronic inflammation and opportunistic pathogen colonization. The severity of the CF-associated lung disease, how3ever, is variable, and disease among patients with identical CFTR genotypes, and a higher concordance in monozygotic compared to dizygotic CF twins, suggest the contribution of non-CFTR genetic factors in the disease. Identification of these secondary genetic factors will broaden our understanding of CF disease and possibly led to new treatments. The delineation of the genetic influences on CF lung disease, however, is not feasible through human studies due to environmental variability, genetic heterogeneity and small sample sizes. Mice deficient of CFTR function "CF mice" generally die of intestinal obstruction by the age of 5 weeks without displaying significant lung disease. Amelioration of the intestinal obstructions by weaning onto a liquid diet, however, results in increased lifespan and consequential disclosure of abnormal lung phenotypes. In particularly, congenic C57BL/6J (B6) CF mice, in the absence of pathogens, spontaneously develop signs of inflammatory lung disease, not unlike those seen in CF patients. In contrast, under the same conditions no sign of lung disease is observed in their control subs or other strains of F mice, including the BALB/cJ (Bc) congenic CF animals. The two congenic strains of CF mice thus provide a means to characterize the factors contributing to the CF lung disease as well as map and characterize secondary genetic factors underlying the differences. The proposed study will employ an in-depth physiological characterization of pulmonary milieu neutrophil function, along with controlled breeding experiments and candidate gene and QTL genetic mapping to identify the factors contributing to the differences in lung phenotypes between the B6 and Bc CF mice, and possibly CF patient variability.
National Institute of Diabetes and Digestive and Kidney Diseases
CFDA Code
DUNS Number
208511808
UEI
JGUJNPJSMYT5
Project Start Date
30-September-1999
Project End Date
31-August-2000
Budget Start Date
Budget End Date
Project Funding Information for 1999
Total Funding
$72,448
Direct Costs
Indirect Costs
Year
Funding IC
FY Total Cost by IC
1999
National Institute of Diabetes and Digestive and Kidney Diseases
$72,448
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 2P50DK049096-06 0008
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 2P50DK049096-06 0008
Patents
No Patents information available for 2P50DK049096-06 0008
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 2P50DK049096-06 0008
Clinical Studies
No Clinical Studies information available for 2P50DK049096-06 0008
News and More
Related News Releases
No news release information available for 2P50DK049096-06 0008
History
No Historical information available for 2P50DK049096-06 0008
Similar Projects
No Similar Projects information available for 2P50DK049096-06 0008